Drug intelligence / Profile preview

supratinib

Development stage: Preclinical
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Oral

Overview

Supratinib is an amphiphilic molecular analogue of the MEK inhibitor selumetinib. It is structurally composed of selumetinib linked to a cholesterol-based tether, facilitating its assembly into stable supramolecular lipid bilayer nanoparticles. This design aims to enhance MEK-driven anti-cancer activity through improved delivery compared to the parent molecule. The therapeutic concept also suggests its potential for integration with immune checkpoint T cell activating biologics to further augment cancer immunotherapy.

Targets

MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)

Beyond the preview

Go deeper on supratinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on supratinib.

Explore the full profile